Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) announced on Monday that it has entered a manufacturing partnership with US-based contract development and manufacturing organisation Made Scientific to advance its autologous CAR-T therapy, HG-CT-1, for relapsed/refractory acute myeloid leukaemia (r/r AML).

Made Scientific will provide technology transfer and manufacturing services from its GMP facilities in Newark and Princeton, New Jersey, which are equipped for both clinical and commercial-scale cell therapy supply. The collaboration is expected to accelerate Hemogenyx's ongoing Phase I clinical trial in adult r/r AML patients and support potential expansion into paediatric cohorts.

Hemogenyx has reported encouraging early clinical data for HG-CT-1, reinforcing confidence in the therapy's safety and potential efficacy.

Headquartered in London with operations in New York, Hemogenyx Pharmaceuticals is developing novel treatments for blood and autoimmune diseases. Made Scientific, backed by South Korea's GC Corporation, specialises in the development and manufacturing of autologous and allogeneic cell therapies.